Showing 2680 results for "amyotrophic lateral sclerosis (ALS)"

FDA Approves Radicava, First New ALS Therapy in 22 Years

The first treatment for amyotrophic lateral sclerosis (ALS) in more than two decades, Radicava (edaravone), has been approved by the  U.S. Food and Drug Administration and will soon be available to patients. The May 5 FDA decision, hailed by physicians and ALS advocates, brings hope to the ALS community that treatment development, after a…

Pfizer, AbbVie Investing $10 Million in Aquinnah’s Neurodegenerative Disease Therapy Approach

Pfizer and AbbVie are pumping $10 million into Aquinnah Pharmaceuticals‘ effort to develop a revolutionary approach to treating neurodegenerative diseases — one that could arrest, or even reverse, the progression of Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s and other conditions. Takeda Pharmaceuticals invested $5 million in Aquinnah’s program in December 2015.

Biohaven Advances Regulatory Efforts for BHV-0223, a Sublingual Form of ALS Therapy Rilutek

Biohaven Pharmaceuticals is pushing hard for regulatory approval and development of its two investigational drugs for amyotrophic lateral sclerosis (ALS): BHV-0223, a sublingual form of Rilutek (riluzole), and BHV-4157, a compound that modulates the neurotransmitter glutamate. After more than 20 years, Rilutek remains the only approved treatment for people with…

Explaining the Early Symptoms of ALS

  In this University of California TV video, Dr. Geoffrey Sheean from the School of Medicine, UC San Diego, talks about the early stages of amyotrophic lateral sclerosis (ALS). MORE: Explaining the progression of ALS Dr. Sheean explains that often the first signs of the…